Sovran Advisors LLC Invests $2.54 Million in Novo Nordisk A/S (NYSE:NVO)

Sovran Advisors LLC acquired a new stake in Novo Nordisk A/S (NYSE:NVO - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 36,559 shares of the company's stock, valued at approximately $2,539,000.

A number of other institutional investors have also recently bought and sold shares of the business. M. Kulyk & Associates LLC lifted its holdings in shares of Novo Nordisk A/S by 3.9% during the 4th quarter. M. Kulyk & Associates LLC now owns 3,182 shares of the company's stock worth $274,000 after acquiring an additional 119 shares during the period. Exencial Wealth Advisors LLC lifted its holdings in shares of Novo Nordisk A/S by 0.5% during the 4th quarter. Exencial Wealth Advisors LLC now owns 23,094 shares of the company's stock worth $1,987,000 after acquiring an additional 124 shares during the period. Dorsey & Whitney Trust CO LLC lifted its holdings in shares of Novo Nordisk A/S by 0.4% during the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 31,494 shares of the company's stock worth $2,709,000 after acquiring an additional 136 shares during the period. BIP Wealth LLC lifted its holdings in shares of Novo Nordisk A/S by 3.9% during the 4th quarter. BIP Wealth LLC now owns 3,642 shares of the company's stock worth $313,000 after acquiring an additional 138 shares during the period. Finally, Xponance Inc. lifted its holdings in shares of Novo Nordisk A/S by 4.9% during the 4th quarter. Xponance Inc. now owns 3,156 shares of the company's stock worth $271,000 after acquiring an additional 146 shares during the period. Institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Trading Up 1.2%

NYSE NVO traded up $0.80 on Friday, hitting $68.50. The company's stock had a trading volume of 5,624,379 shares, compared to its average volume of 7,239,527. The company has a quick ratio of 0.56, a current ratio of 0.74 and a debt-to-equity ratio of 0.70. Novo Nordisk A/S has a 1-year low of $57.00 and a 1-year high of $145.99. The company's 50-day moving average is $69.11 and its 200 day moving average is $77.04. The firm has a market cap of $305.85 billion, a PE ratio of 20.27, a PEG ratio of 1.22 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.92. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. The firm had revenue of $11.87 billion during the quarter. As a group, analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

NVO has been the subject of a number of recent analyst reports. Wall Street Zen raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Saturday, June 14th. BMO Capital Markets reissued a "market perform" rating and issued a $64.00 price objective (down previously from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Kepler Capital Markets raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Thursday, March 13th. Guggenheim downgraded shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, April 17th. Finally, Dbs Bank downgraded shares of Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $112.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.